Jacquelyn A. Hank

Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study

Suzanne Shusterman, Wendy B. London, Stephen D. Gillies et al. · Journal of Clinical Oncology · 2010 · 242 citations · Full text

Medicine, Oncology, Pharmacology +13

Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

Alice L. Yu, Andrew L. Gilman, M. Fevzi Özkaynak et al. · Clinical Cancer Research · 2021 · 216 citations · Full text

Life Sciences, Immunology, Oncology +17

Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children’s Oncology Group

Rajen Mody, Alice L. Yu, Arlene Naranjo et al. · Journal of Clinical Oncology · 2020 · 191 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group

Kaci L. Osenga, Jacquelyn A. Hank, Mark R. Albertini et al. · Clinical Cancer Research · 2006 · 180 citations · Full text

Medicine, Oncology, Pediatrics +17

Genotypes of NK Cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy

David Delgado, Jacquelyn A. Hank, Jill Kolesar et al. · Cancer Research · 2010 · 176 citations · Full text

Life Sciences, Immunology, Oncology +17